confused re the $4-6m.

During the week EMS came out with an announcement advising RM Capital were given a mandate to raise $4M to $6M.

However HC Berlin Pharma advises that funding has been secured and that RM themselves are the investors.

So what's going on ?

"Financing of trials for anti-malaria treatment secured


Berlin, March 5, 2009 – HC Berlin Pharma AG, a company listed on the Open Market of the Frankfurt Stock Exchange, announces that the financing of the last clinical trial phase of the antimalaria treatment ArTiMist™ is secured. Investor is the Corporate Finance company RM Corporate Finance Pty. Ltd. Australia.

ArTiMist™ is the flagship product of the German pharmaceutical company and its Australian partner company Eastland Medical Systems Ltd., and especially developed for infants and children, which is administered as a sublingual spray. This new method of delivery allows direct access to the blood circulation and shows considerable advantages compared with conventional treatments.

“We are pleased that we can bring ArTiMist™ into this phase of the last clinical trials now. We are working together with our Australian partner Eastland Medical Systems Ltd in intensive negotiations with different African states about the realisation of the field studies in their countries and will reach agreements shortly“, so Ottmar W. Geiger, CEO of the HC Berlin Pharma AG.

“Now we are getting a big step closer to a quick market entry of ArTiMist™“, explains Rudolf W. Schötteldreier, chairman of the board of the HC Berlin Pharma AG. “In accordance with Eastland Medical Systems Ltd. after the end of the phase III studies we will start to coordinate the marketing“, so Schötteldreier finally.

Further information on HC Berlin Pharma AG please see www.hcberlinpharma.ag.

For detailed information please contact directly our Investor Relations Team:

esVedra consulting GmbH
t: +49. 89. 28 80 81 33
f: +49. 89. 28 80 81 49
[email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.esvedra-consulting.com"